119256-94-9

Basic information

• Product Name: 2,2-dibutyl-5-(quinolin-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-ol
• Synonyms: 1-Naphthalenol, 2,2-dibutyl-1,2,3,4-tetrahydro-5-(2-quinolinylmethoxy)-; 2,2-Dibutyl-5-(2-quinolylmethoxy)-1,2,3,4-tetrahydro-1-naphthol
• CAS NO: 119256-94-9
• Molecular Formula: C₂₈H₃₅NO₂
• Molecular Weight: 417.583
• Mol File: 119256-94-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 573.2°C at 760 mmHg
• Flash Point: 300.5°C
• Density: 1.084g/cm³
• Vapor Pressure: 5.59E-14mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 2,2-dibutyl-5-(quinolin-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-dibutyl-5-(quinolin-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-ol(119256-94-9)
• EPA Substance Registry System: 2,2-dibutyl-5-(quinolin-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalen-1-ol(119256-94-9)

Safety Data

• Hazardous Substances Data: 119256-94-9(Hazardous Substances Data)

Usage

Chemical family

Tetrahydronaphthalen-1-ol derivatives

Type of compound

Synthetic compound

Potential applications

Pharmacological properties

Research focus

Medicinal and pharmaceutical research

Purpose

Development of new drugs for various conditions

Molecular structure

Unique, making it a promising candidate for further investigation

Upstream product

• 4377-41-7 2-Chloromethylquinoline 
• 60-29-7 diethyl ether 
• 119229-17-3 2,2-dibutyl-3,4-dihydro-5-(2-quinolylmethoxy)-1(2H)-naphthalenone 
• 119229-02-6 2,2-dibutyl-3,4-dihydro-5-methoxy-1(2H)-naphthalenone 
• 119229-03-7 2,2-dibutyl-3,4-dihydro-5-hydroxy-1(2H)-naphthalenone 
• 33892-75-0 5-Methoxy-1-tetralone 

Relevant articles and documents

Studies on 5-lipoxygenase inhibitors. II. Discovery, optical resolution and enantioselective synthesis of FR110302, a highly potent non-redox type 5- lipoxygenase inhibitor

A novel series of 2,2-dialkyl-5-(2-quinolylmethoxy)-1,2,3,4-tetrahydro- 1-naphthols was synthesized and evaluated as 5-lipoxygenase (5-LO) inhibitors. Systematic optimization led to identification of several highly potent non-redox type 5-LO inhibitors with nanomolar IC50s as racemic mixtures. Optical resolution of racemate 50 indicated that its 5-LO inhibitory activity was enantiospecific and due to the (+)-enantiomer. An efficient synthetic route to the (+)-enantiomers via asymmetric reduction of tetralone intermediates was established. The best compound, (+)-2,2-dibutyl- 5-(2-quinolylmethoxy)-1,2,3,4-tetrahydro-1-naphthol (FR110302, (+)-50), showed potent inhibitory activity against leukotriene (LT) biosynthesis by intact neutrophiles in rats (IC50 4.9 nM) and in humans (IC50 40 nM). Furthermore oral administration of FR110302 significantly inhibited neutrophil migration in the rat air pouch model at 1 mg/kg.

Quinolyl methoxy compounds, processes for preparation thereof and pharmaceutical composition comprising the same

The invention relates to a method of treating arteriosclerosis or pancreatitis comprising administering a compound of the formula: STR1 wherein A is STR2 R1 is quinolyl, R2 is hydrogen or lower alkyl, R3 is lower alkyl, X is hydrogen, halogen, hydroxy or lower alkyl, m is an integer 1 or 2, and n is an integer 1 to 4, or pharmaceutically acceptable salts thereof.